According to a recent LinkedIn post from Neuromod Devices Ltd, the company is exhibiting at the 2026 Joint Defense Veterans Audiology Conference at the DoubleTree by Hilton in Orlando, Florida. The post highlights that Neuromod is promoting Lenire, described as an FDA-approved bimodal neuromodulation device for tinnitus, at Booth 11 to conference attendees.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post suggests that Lenire is now available as a treatment option for an estimated 3.2 million veterans living with tinnitus through the U.S. Department of Veterans Affairs. This positioning within the VA system may indicate access to a large, defined patient population, which could be significant for long-term revenue generation and reimbursement stability.
By emphasizing VA availability and clinical positioning at a defense-focused audiology conference, the post implies Neuromod is targeting institutional adoption rather than solely retail or private practice channels. For investors, this focus on government and veterans’ healthcare pathways may signal a strategic effort to secure recurring demand and strengthen the company’s footprint in the U.S. tinnitus treatment market.